Jochen Hanns-Martin Lorch

Medicine & Life Sciences

1. Anaplastic Thyroid Carcinoma 100%
2. Head and Neck Neoplasms 84%
3. Squamous Cell Carcinoma of Head and Neck 70%
4. Survival 54%
5. Oropharyngeal Neoplasms 52%
6. Squamous Cell Carcinoma 52%
7. Neoplasms 49%
8. Papillary Thyroid Cancer 41%
9. Induction Chemotherapy 41%
10. Everolimus 36%
11. Medullary Thyroid cancer 34%
12. Radiotherapy 34%
13. Adenoid Cystic Carcinoma 33%
14. Therapeutics 31%
15. Squamous Cell Neoplasms 27%
16. Phosphatidylinositol 3-Kinases 27%
17. Merkel Cell Carcinoma 26%
18. Chemoradiotherapy 25%
19. Mouth 23%
20. avelumab 22%
21. Radiation 22%
22. Mutation 21%
23. Drug Therapy 20%
24. Nivolumab 19%
25. Progression-Free Survival 19%
26. Re-Irradiation 18%
27. Fluorouracil 18%
28. Human papillomavirus 16 18%
29. Cisplatin 18%
30. Recurrence 17%
31. Gastrostomy 16%
32. Neck 16%
33. Biomarkers 16%
34. Docetaxel 15%
35. T-Lymphocytes 15%
36. Immunotherapy 15%
37. Trastuzumab 15%
38. Tumor Burden 15%
39. Carcinoma 15%
40. Head 15%
41. Nasopharyngeal Carcinoma 14%
42. Thyroid Gland 14%
43. Patient Reported Outcome Measures 14%
44. Ketogenic Diet 14%
45. High-Throughput Nucleotide Sequencing 14%
46. Protein-Tyrosine Kinases 13%
47. Human Herpesvirus 4 12%
48. Antibodies 12%
49. Disease-Free Survival 12%